Quantum Bio filed IND for Lucid-MS to start Phase II in multiple sclerosis

Canada-based Quantum BioPharma (Nasdaq: QNTM) submitted an IND application to the US FDA for Lucid-21-302, known as Lucid-MS, a small-molecule drug candidate intended for the treatment of multiple sclerosis, [according to a company announcement](https://www.globenewswire.com/news-release/2026/04/01/3266579/0/en/Quantum-BioPharma-Submits-Investigational-New-Drug-IND-Application-to-United-States-Food-and-Drug-Administration-FDA-for-Lucid-MS-Phase-Two-Clinical-Trial-in-Multiple-Sclerosis.html). The submission supports a planned Phase II clinical trial, with an FDA response anticipated in Q2 2026. Multiple sclerosis affects approximately 2.8 million people worldwide, according to the Atlas of MS Third Edition published via PubMed Central. The disease is characterized by immune-mediated attacks on the myelin sheath surrounding nerve fibers, leading to progressive neurological disability. Despite more than two decades of drug approvals, the existing treatment landscape is dominated by agents that suppress or modulate immune activity — interferons, glatiramer acetate, S1P receptor modulators, anti-CD20 antibodies — none of which directly target the demyelination process itself. The absence of any approved remyelination or myelin-protective therapy represents the field's most persistent gap, particularly for patients with progressive forms of the disease where immune-targeting drugs offer limited benefit. Lucid-MS is described by Quantum BioPharma as a patented new chemical entity designed to inhibit demyelination and provide neuroprotection. The company has not disclosed a specific molecular target or mechanism beyond the functional characterization of myelin preservation; no INN or chemical identifier has been made public. The company positions the compound as mechanistically distinct from approved disease-modifying therapies, arguing that it addresses neurodegeneration directly rather than upstream immune dysregulation. In preclinical models, the company states the compound prevented and reversed myelin degradation, though the full preclinical dataset has not been published in a peer-reviewed forum. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/lucid-ms-ind-application-quantum-biopharma)